Namir Hassan, PhD

Namir Hassan joined Zelluna Immunotherapy in August 2018 to serve as Chief Scientific Officer and subsequently as Chief Executive Officer from 2019. He has over 15 years of biotech and pharma industry experience spanning target validation through to early phase clinical trials with most of that spent on Immunotherapies. Prior to joining Zelluna, Namir was a VP at Immunocore, responsible for creating and growing the infectious disease unit and pipeline as well as helping to secure up to $40M of funding for the organisation. During his tenure with the company, Namir was also responsible for overseeing and strategically expanding biology, preclinical, biomarkers and development for the Oncology portfolio as well as successfully leading, the first in human study with KIMMTRAK, the first ever T Cell Receptor (TCR) bispecific subsequently approved for the treatment of uveal melanoma.